GlassScriptPhysician profile
Madeline V Grant
NPI 1326763921
$7,321.66
in general payments reported to CMS, 2019-2025
51 companies · $2,419 in 2025
The $2,419 reported for 2025 was more than what 95% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $2,078 · 2024: $2,825 · 2025: $2,419.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,769 · Education: $552.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,769.18 |
| Education | $552.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $444.25 | 2023-2025 | Jaypirca, Verzenio |
| Incyte Corporation | $443.84 | 2023-2025 | Jakafi, Monjuvi, Zynyz |
| Novartis Pharmaceuticals Corporation | $437.77 | 2023-2025 | |
| Daiichi Sankyo INC. | $431.97 | 2023-2025 | Enhertu |
| Celgene Corporation | $403.91 | 2023-2025 | Reblozyl, Opdualag, Pomalyst |
| Pfizer INC. | $385.27 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $384.30 | 2023-2025 | Opdivo, Opdualag |
| Astrazeneca Pharmaceuticals LP | $340.73 | 2023-2025 | Enhertu, Imfinzi, Calquence |
| Merck Sharp & Dohme LLC | $326.43 | 2024-2025 | Keytruda, Lynparza, Welireg |
| Takeda Pharmaceuticals U.S.A., INC. | $322.05 | 2023-2025 | Ninlaro, Fruzaqla, Alunbrig |
| Sobi, INC | $257.57 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $247.86 | 2023-2025 | |
| Exelixis INC. | $221.04 | 2023-2025 | Cabometyx |
| Janssen Biotech, INC. | $220.58 | 2023-2025 | Tecvayli, Darzalex, Rybrevant |
| Astellas Pharma US INC | $203.31 | 2024-2025 | Padcev, Vyloy, Xtandi |
Show all 51 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $194.41 | 2023-2025 | Trodelvy |
| Abbvie INC. | $149.71 | 2024-2025 | |
| Glaxosmithkline, LLC. | $139.69 | 2024-2025 | Ojjaara, Zejula, Jemperli |
| Eisai INC. | $125.86 | 2023-2025 | |
| Genentech USA, INC. | $115.74 | 2023-2025 | Tecentriq, Alecensa, Polivy |
| Jazz Pharmaceuticals INC. | $98.37 | 2023-2025 | |
| Sumitomo Pharma America, INC. | $91.66 | 2024-2025 | Orgovyx |
| Array Biopharma INC | $86.03 | 2023-2025 | Braftovi, Lorbrena, Mektovi |
| Puma Biotechnology, INC. | $85.87 | 2023-2025 | |
| Kite Pharma, INC. | $81.66 | 2023-2025 | Yescarta |
| Seagen INC. | $74.24 | 2023 | Tukysa, Padcev, Adcetris |
| Alexion Pharmaceuticals, INC. | $72.98 | 2023-2025 | Ultomiris |
| Stemline Therapeutics INC. | $70.78 | 2023-2025 | Orserdu |
| Boehringer Ingelheim Pharmaceuticals, INC. | $70.61 | 2023-2025 | Gilotrif |
| Pharmaessentia USA Corporation | $63.13 | 2024-2025 | Besremi |
| Aveo Pharmaceuticals, INC. | $62.88 | 2023-2025 | Fotivda |
| Geron Corporation | $59.48 | 2025 | Rytelo |
| Mirati Therapeutics, INC. | $57.38 | 2023-2024 | Krazati |
| Agios Pharmaceuticals, INC. | $57.02 | 2023-2024 | Pyrukynd |
| Rigel Pharmaceuticals, INC. | $55.55 | 2024 | Rezlidhia, Tavalisse |
| Emd Serono, INC. | $43.87 | 2023-2025 | Bavencio |
| Janssen Scientific Affairs, LLC | $41.18 | 2025 | Carvykti, Tecvayli, Talvey |
| Deciphera Pharmaceuticals INC. | $40.74 | 2023-2024 | Qinlock |
| Beigene USA, INC. | $39.22 | 2024-2025 | Brukinsa |
| Blueprint Medicines Corporation | $35.00 | 2024 | Ayvakit |
| Pharmacyclics LLC, An Abbvie Company | $32.67 | 2023 | Imbruvica, Epkinly |
| Acrotech Biopharma INC. | $31.75 | 2024 | Beleodaq |
| Dendreon Pharmaceuticals LLC | $27.60 | 2023 | Provenge |
| Servier Pharmaceuticals LLC | $20.38 | 2024 | |
| Immunocore Limited | $19.94 | 2024 | Kimmtrak |
| Genmab U.S., INC. | $19.41 | 2023 | Epkinly |
| Syndax Pharmaceuticals, INC. | $18.76 | 2025 | |
| Morphosys, US INC. | $18.08 | 2023 | Monjuvi |
| Taiho Oncology, INC. | $16.57 | 2024 | |
| Genzyme Corporation | $16.34 | 2023 | |
| G1 Therapeutics, INC. | $16.22 | 2023 | Cosela |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Madeline Grant listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.